Pituitary and ovarian function in women receiving hormonal contraception

Brian L. Cohen, Maurice Katz

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

A study was performed to further evaluate pituitaryovarian function in women receiving an oral contraceptive preparation. Basal hormone levels (follicle stimulating hormone, luteinizing hormone, estradiol and prolactin) and gonadotropic response to gonadotropic releasing hormone were studied in 12 healthy, regularly ovulating women in the early follicular and mid-luteal phases of their menstrual cycle (non-treatment control period). These same uomen were then given NORDETTE (ethinyl estradiol 30 μg + d-Norgestrel 150 μg) cyclically for 3 months. In the third month of treatment, the tests were repeated on day 21, i.e. after 21 active pills, and on day 28, i.e. after 21 active and 7 inactive tablets. On active preparation, basal luteinizing hormone, follicle stimulating hormone and estradiol and gonadotropin response to gonadotropin releasing hormone were significantly suppressed. However, by day 28 (after completion of the inactive tablets), basal gonadotropin and estradiol concentrations and the gonadotropic response to gonadotropic releasing hormone were not significantly different to their pretreatment levels. No consistent change in prolactin concentration occurred as a result of oral contraceptive therapy. These results indicate that the 'active' component of even a relatively lou-dose pill causes considerable suppression of pituitary-ovarian function but that after 7 days of placebo, pituitary function and basal sstradiol secretion have virtually returned to normal.

Original languageEnglish (US)
Pages (from-to)475-487
Number of pages13
JournalContraception
Volume20
Issue number5
DOIs
StatePublished - 1979
Externally publishedYes

Fingerprint

Contraception
Estradiol
Follicle Stimulating Hormone
Hormones
Oral Contraceptives
Luteinizing Hormone
Gonadotropins
Prolactin
Tablets
Norgestrel
Ethinyl Estradiol
Luteal Phase
Gonadotropin-Releasing Hormone
Placebos
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Pituitary and ovarian function in women receiving hormonal contraception. / Cohen, Brian L.; Katz, Maurice.

In: Contraception, Vol. 20, No. 5, 1979, p. 475-487.

Research output: Contribution to journalArticle

Cohen, Brian L. ; Katz, Maurice. / Pituitary and ovarian function in women receiving hormonal contraception. In: Contraception. 1979 ; Vol. 20, No. 5. pp. 475-487.
@article{19f193830a5d45f89fd8438768b6a3e3,
title = "Pituitary and ovarian function in women receiving hormonal contraception",
abstract = "A study was performed to further evaluate pituitaryovarian function in women receiving an oral contraceptive preparation. Basal hormone levels (follicle stimulating hormone, luteinizing hormone, estradiol and prolactin) and gonadotropic response to gonadotropic releasing hormone were studied in 12 healthy, regularly ovulating women in the early follicular and mid-luteal phases of their menstrual cycle (non-treatment control period). These same uomen were then given NORDETTE (ethinyl estradiol 30 μg + d-Norgestrel 150 μg) cyclically for 3 months. In the third month of treatment, the tests were repeated on day 21, i.e. after 21 active pills, and on day 28, i.e. after 21 active and 7 inactive tablets. On active preparation, basal luteinizing hormone, follicle stimulating hormone and estradiol and gonadotropin response to gonadotropin releasing hormone were significantly suppressed. However, by day 28 (after completion of the inactive tablets), basal gonadotropin and estradiol concentrations and the gonadotropic response to gonadotropic releasing hormone were not significantly different to their pretreatment levels. No consistent change in prolactin concentration occurred as a result of oral contraceptive therapy. These results indicate that the 'active' component of even a relatively lou-dose pill causes considerable suppression of pituitary-ovarian function but that after 7 days of placebo, pituitary function and basal sstradiol secretion have virtually returned to normal.",
author = "Cohen, {Brian L.} and Maurice Katz",
year = "1979",
doi = "10.1016/0010-7824(79)90053-2",
language = "English (US)",
volume = "20",
pages = "475--487",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Pituitary and ovarian function in women receiving hormonal contraception

AU - Cohen, Brian L.

AU - Katz, Maurice

PY - 1979

Y1 - 1979

N2 - A study was performed to further evaluate pituitaryovarian function in women receiving an oral contraceptive preparation. Basal hormone levels (follicle stimulating hormone, luteinizing hormone, estradiol and prolactin) and gonadotropic response to gonadotropic releasing hormone were studied in 12 healthy, regularly ovulating women in the early follicular and mid-luteal phases of their menstrual cycle (non-treatment control period). These same uomen were then given NORDETTE (ethinyl estradiol 30 μg + d-Norgestrel 150 μg) cyclically for 3 months. In the third month of treatment, the tests were repeated on day 21, i.e. after 21 active pills, and on day 28, i.e. after 21 active and 7 inactive tablets. On active preparation, basal luteinizing hormone, follicle stimulating hormone and estradiol and gonadotropin response to gonadotropin releasing hormone were significantly suppressed. However, by day 28 (after completion of the inactive tablets), basal gonadotropin and estradiol concentrations and the gonadotropic response to gonadotropic releasing hormone were not significantly different to their pretreatment levels. No consistent change in prolactin concentration occurred as a result of oral contraceptive therapy. These results indicate that the 'active' component of even a relatively lou-dose pill causes considerable suppression of pituitary-ovarian function but that after 7 days of placebo, pituitary function and basal sstradiol secretion have virtually returned to normal.

AB - A study was performed to further evaluate pituitaryovarian function in women receiving an oral contraceptive preparation. Basal hormone levels (follicle stimulating hormone, luteinizing hormone, estradiol and prolactin) and gonadotropic response to gonadotropic releasing hormone were studied in 12 healthy, regularly ovulating women in the early follicular and mid-luteal phases of their menstrual cycle (non-treatment control period). These same uomen were then given NORDETTE (ethinyl estradiol 30 μg + d-Norgestrel 150 μg) cyclically for 3 months. In the third month of treatment, the tests were repeated on day 21, i.e. after 21 active pills, and on day 28, i.e. after 21 active and 7 inactive tablets. On active preparation, basal luteinizing hormone, follicle stimulating hormone and estradiol and gonadotropin response to gonadotropin releasing hormone were significantly suppressed. However, by day 28 (after completion of the inactive tablets), basal gonadotropin and estradiol concentrations and the gonadotropic response to gonadotropic releasing hormone were not significantly different to their pretreatment levels. No consistent change in prolactin concentration occurred as a result of oral contraceptive therapy. These results indicate that the 'active' component of even a relatively lou-dose pill causes considerable suppression of pituitary-ovarian function but that after 7 days of placebo, pituitary function and basal sstradiol secretion have virtually returned to normal.

UR - http://www.scopus.com/inward/record.url?scp=0018606857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018606857&partnerID=8YFLogxK

U2 - 10.1016/0010-7824(79)90053-2

DO - 10.1016/0010-7824(79)90053-2

M3 - Article

C2 - 393456

AN - SCOPUS:0018606857

VL - 20

SP - 475

EP - 487

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 5

ER -